NCT02559310: A reported trial by Nabriva Therapeutics AG
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT02559310 |
|---|---|
| Title | A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Lefamulin (BC 3781) Versus Moxifloxacin (With or Without Adjunctive Linezolid) in Adults With Community-Acquired Bacterial Pneumonia |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Sept. 30, 2015 |
| Completion date | April 30, 2017 |
| Required reporting date | April 30, 2020, midnight |
| Actual reporting date | Aug. 28, 2019 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |